Recent data report that abiraterone acetate, a specific inhibitor of CYP17 that is key to
androgen and estrogen synthesis, improves survival in metastatic castration-resistant …

Purpose Metastatic castration resistant prostate cancer with low baseline prostate specific
antigen represents an early stage in the natural history of castration resistant prostate cancer …

Abstract Purpose: The EGF receptor (EGFR) is overexpressed in the majority of metastatic
castration-resistant prostate cancers (mCRPC) and might represent a valid therapeutic …

e16055 Background: Previous trials of the antiangiogenic kinase inhibitor sorafenib in
mCRPC have reported PSA elevation accompanying radiographic response, and evidence …

Taxanes–docetaxel and cabazitaxel–are the most active chemotherapy drugs currently used
for the treatment of metastatic castration-resistant prostate cancer (mCRPC). However …

Background: Determining the maximum tolerated dose (MTD) and the dose-limiting toxicity
(DLT) of sorafenib (S) plus imatinib (IM) in castration-resistant prostate cancer (CRPC) …

5017 Background: mCRPC commonly has hyperactivated PI3K/Akt signaling, usually via
PTEN loss; androgen receptor (AR) blockade activates Akt, supporting mCRPC cell survival …

Background The inhibition of insulin-like growth factor receptor-1 (IGF-1R) induces cell cycle
arrest and enhancing the effect of castration by delay of progression of human prostate …

Radium‑223 has improved overall survival (OS) and reduced symptomatic skeletal events
(SSE) in patients with metastatic castration‑resistant prostate cancer (mCRPC) and bone …

Background Few options are available after taxane-based therapy in men with CRPC.
Genetic alterations involving the mTOR pathway have been associated with CRPC …